title: Emerging treatment options for benign prostatic obstruction.
abstract: Benign prostatic obstruction (BPO) affects an increasing number of men with age. It can cause troublesome lower urinary tract symptoms, can have a negative impact on quality of life, and may be associated with significant morbidity. Currently available medication and surgical treatments are limited by adverse events, invasiveness, and patient compliance. This has driven research into the pathogenesis of benign prostatic hyperplasia and led to the development of novel pharmacological agents and minimally invasive therapeutic interventions. This review highlights emerging treatment options for BPO.
authors.affiliation: Bristol Urological Institute, Southmead Hospital, Bristol, UK.
authors.forename: Brian A
authors.initials: BA
authors.lastname: Parsons
authors.forename: Hashim
authors.initials: H
authors.lastname: Hashim
mesh_terms: D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D011379:Prognosis; D011470:Prostatic Hyperplasia / Q000150:complications* / Q000628:therapy; D011788:Quality of Life; D014524:Urethral Obstruction / Q000209:etiology / Q000628:therapy*; D014555:Urination Disorders / Q000209:etiology / Q000628:therapy*; D013521:Urologic Surgical Procedures, Male / Q000379:methods*
chemical_list: D007166:Immunosuppressive Agents; D010726:Phosphodiesterase Inhibitors